Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Myriad Genetics Inc Raises FY 2014 Guidance


Tuesday, 5 Nov 2013 04:05pm EST 

Myriad Genetics Inc announced that it has raised its revenue guidance for fiscal 2014. It expects revenues of $700 to $715 million, compared to previous guidance of $690 to $710 million. This new guidance represents 14 to 17% revenue growth when compared to the fiscal 2013. Myriad is also increasing its diluted earnings per share (EPS) guidance for fiscal 2014. The Company is projecting diluted earnings per share of $1.92 to $1.97 compared to previous guidance of $1.87 to $1.94. This new guidance represents 9 to 12% EPS growth. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $692 million and EPS of $1.87 for fiscal 2014. 

Company Quote

36.65
0.15 +0.41%
26 Dec 2014